Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVNS
AVNS logo

AVNS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Avanos Medical Inc (AVNS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
24.960
1 Day change
-0.08%
52 Week Range
25.490
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

AVNS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading very close to the announced cash acquisition price of $25.00, so upside from here is minimal. With the deal vote scheduled for July 22, 2026, the current setup looks like a near-arbitrage situation rather than a strong long-term investment. Since the user is impatient and does not want to wait for optimal entry points, the better decision is to avoid buying now and take the cash-merger value already priced into the shares.

Technical Analysis

Technically, AVNS is in a mildly constructive short-term structure but with limited relevance given the merger context. Price closed at 24.99, essentially at the $25.00 deal price. MACD histogram is negative at -0.166, though it is contracting, which suggests downside momentum is easing. RSI_6 at 57.619 is neutral, showing no overbought or oversold extreme. Moving averages are bullish with SMA_5 > SMA_20 > SMA_200, supporting a positive trend, but the stock is effectively capped near the merger consideration. Key levels are tight around the current price: Pivot 25.075, R1 25.358, S1 24.793, S2 24.618. The stock trend model shows a 60% chance of +1.1% next day and +2.8% next week, but a -0.06% expected move over the next month, which reinforces the limited medium-term upside.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish based on the open interest put-call ratio of 0.47, meaning call interest is higher than put interest. However, option volume is extremely light with only 9 contracts traded, so the signal is not very strong. Implied volatility is very elevated at 164.27 with IV percentile 94.84 and IV rank 79.85, which is consistent with a special situation/deal-driven name rather than a normal directional trade. Put open interest is 2231 versus call open interest of 4755, supporting a modest bullish bias, but the merger price limits meaningful upside.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
8

Positive Catalysts

  • ["Announced sale to American Industrial Partners at $25.00 per share in cash", "Deal vote scheduled for July 22, 2026, providing a clear event-driven catalyst", "Technical trend remains above long-term moving averages", "Options positioning shows more call than put interest"]

Neutral/Negative Catalysts

  • ["Current price is already essentially at the $25.00 acquisition price, leaving little upside", "MACD remains negative, indicating momentum is still not fully supportive", "No strong hedge fund or insider buying trend", "No recent congress trading activity to support a bullish thesis", "Very light option volume makes sentiment less reliable"]

Financial Performance

No usable financial snapshot was provided because the data returned an error, so there is no reliable latest-quarter season or growth update to assess. Based on the information available, the investment case is being driven primarily by the pending acquisition rather than recent operating fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or target-change data was provided in the dataset, so there is no visible trend in Wall Street estimates to summarize. In this situation, the pros view is that the acquisition creates clear near-term price support around $25.00, while the cons view is that the stock offers very limited upside from current levels because the deal value appears already reflected in the market price.

Wall Street analysts forecast AVNS stock price to rise
Analyst Rating
0
Wall Street analysts forecast AVNS stock price to rise
Buy
Hold
Sell
0
Current: 24.980
sliders
Low
0
Averages
0
High
0
0
Current: 24.980
sliders
Low
0
Averages
0
High
0
Barclays
NULL -> Overweight
upgrade
$9 -> $11
AI Analysis
2026-01-16
Reason
Barclays
Price Target
$9 -> $11
AI Analysis
2026-01-16
upgrade
NULL -> Overweight
Reason
Barclays raised the firm's price target on Aveanna to $11 from $9 and keeps an Overweight rating on the shares. The firm upped estimates post the company's Q4 preannouncement.
William Blair
Jared Haase
Outperform
initiated
2025-12-08
Reason
William Blair
Jared Haase
Price Target
2025-12-08
initiated
Outperform
Reason
William Blair analyst Jared Haase initiated coverage of Aveanna with an Outperform rating. Preferred payers are producing a more respectable growth algorithm, the analyst tells investors in a research note. Aveanna is positioned as an attractive smid-cap healthcare services holding, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AVNS
Unlock Now

People Also Watch